Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...
A number of first-in-disease, first-in-class and first-in-modality drugs approved last year have redefined therapeutic areas, ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug A ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday ...
Dyne Therapeutics Inc. 2.97% $1.44B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback